|
|
Volumn 344, Issue , 2012, Pages
|
|
NICE backs leukaemia drug after manufacturer drops price.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
4 METHYL N (3 (4 METHYLIMIDAZOL 1 YL) 5 (TRIFLUOROMETHYL)PHENYL) 3 ((4 PYRIDIN 3 YLPYRIMIDIN 2 YL)AMINO)BENZAMIDE;
4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE;
ANTINEOPLASTIC AGENT;
DASATINIB;
IMATINIB;
PIPERAZINE DERIVATIVE;
PYRIMIDINE DERIVATIVE;
THIAZOLE DERIVATIVE;
CHRONIC MYELOID LEUKEMIA;
COST BENEFIT ANALYSIS;
ECONOMICS;
HUMAN;
NOTE;
PRACTICE GUIDELINE;
UNITED KINGDOM;
ANTINEOPLASTIC AGENTS;
COST-BENEFIT ANALYSIS;
GREAT BRITAIN;
HUMANS;
LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;
PIPERAZINES;
PRACTICE GUIDELINES AS TOPIC;
PYRIMIDINES;
THIAZOLES;
MLCS;
MLOWN;
|
|
EID: 84860554832
PISSN: None
EISSN: 17561833
Source Type: Journal
DOI: 10.1136/bmj.e2274 Document Type: Note |
|
Times cited : (1)
|
|
References (0)
|
